Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05383209 · ClinicalTrials.gov registry record · Phase 2
Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)
A Phase 2 study, sponsored by EyePoint Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
NCT05383209 is a Phase 2 study that has completed, run by EyePoint Pharmaceuticals. The registered enrollment target is 77 participants.
The verdict
NCT05383209, a Phase 2 study, has completed, sponsored by EyePoint Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
Study Summary
A prospective, randomized, double-masked study that evaluated the ocular efficacy and safety of two doses of the EYP-1901 intravitreal (IVT) insert compared to sham.
Interventions
- DRUG EYP-1901
- OTHER Sham IVT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2022-09-28 |
| Est. Completion | 2024-05-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05383209
The ClinicalTrials.gov registry entry for NCT05383209 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EyePoint Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which EYP-1901 is the first listed.
NCT05383209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05383209 about?
NCT05383209 is a clinical study titled "Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)". A prospective, randomized, double-masked study that evaluated the ocular efficacy and safety of two doses of the EYP-1901 intravitreal (IVT) insert compared to sham.
What is the current status of trial NCT05383209?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2022-09-28. Estimated completion is 2024-05-06.
What interventions are being tested in trial NCT05383209?
The interventions under investigation include: EYP-1901 (DRUG), Sham IVT (OTHER).
Who is sponsoring clinical trial NCT05383209?
This trial is sponsored by EyePoint Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.